Star Combo Pharma Limited (ASX:S66)

ALERT: Price-sensitive ASX Announcement for S66

Current share price for S66 : $0.130 -0.075 (-36.59%)⁺

Announcement

S66 Dec 25 Half Year Report and Financial Statements

Release

25 Feb 2026 2:14PM

Price at Release

$0.205

Full Release

Summary

Star Combo Pharma Limited's half-year report for the period ending 31 December 2025 details a 24% decrease in revenue compared to the previous year, attributed to the loss of a major OEM contract, the closure of the Austoyou retail business, and a reduction in their own brand sales. The company reported a profit after tax of AUD 413,243, up 49% from the prior period. Total comprehensive income attributable to shareholders rose by 78% to AUD 466,409. The board has recommended that no dividends be paid for the period. The company remains focused on growing its contract manufacturing operations and plans to expand its manufacturing capacity at Smithfield. No significant changes occurred in the company's operations or state of affairs during the period.

Key Points

Revenue decreased by 24% compared to the previous year.
Closure of Austoyou retail business and loss of a major OEM contract affected revenue.
Profit after tax increased by 49% to AUD 413,243.
Total comprehensive income attributable to shareholders rose by 78%.
No dividends were recommended for the period.
Focus remains on growing contract manufacturing operations.
Plans to expand manufacturing capacity at Smithfield.
No significant changes in operations or state of affairs during the period.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.